Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Impaired Fat Oxidation During Exercise in Long-Chain Acyl-CoA Dehydrogenase Deficiency Patients and Effect of IV-Glucose

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Genotype and phenotype classification of 29 patients affected by Krabbe disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Allan M Lund
  • Line Borgwardt
  • Federica Cattaneo
  • Diego Ardigò
  • Silvia Geraci
  • Mercedes Gil-Campos
  • Linda De Meirleir
  • Cécile Laroche
  • Philippe Dolhem
  • Duncan Cole
  • Anna Tylki-Szymanska
  • Monica Lopez-Rodriguez
  • Encarna Guillén-Navarro
  • Christine I Dali
  • Bénédicte Héron
  • Jens Fogh
  • Nicole Muschol
  • Dawn Phillips
  • J M Hannerieke Van den Hout
  • Simon A Jones
  • Yasmina Amraoui
  • Paul Harmatz
  • Nathalie Guffon
Vis graf over relationer

INTRODUCTION: Long-term outcome data provide important insights into the clinical utility of enzyme replacement therapies. Such data are presented for velmanase alfa in the treatment of alpha-mannosidosis (AM).

METHODS: Patient data (n = 33; 14 adults, 19 paediatric) from the clinical development programme for velmanase alfa were integrated in this prospectively-designed analysis of long-term efficacy and safety. Patients who participated in the phase I/II or phase III trials and were continuing to receive treatment after completion of the trials were invited to participate in a comprehensive evaluation visit to assess long-term outcomes. Primary endpoints were changes in serum oligosaccharide and the 3-minute stair climb test (3MSCT).

RESULTS: Mean (SD) treatment exposure was 29.3 (15.2) months. Serum oligosaccharide levels were significantly reduced in the overall population at 12 months (mean change: -72.7%, P < 0.001) and remained statistically significant at last observation (-62.8%, P < 0.001). A mean improvement of +9.3% in 3MSCT was observed at 12 months (P = 0.013), which also remained statistically significant at last observation (+13.8%, P = 0.004), with a more pronounced improvement detected in the paediatric subgroup. No treatment-emergent adverse events were reported leading to permanent treatment discontinuation.

CONCLUSIONS: Patients treated with velmanase alfa experienced improvements in biochemical and functional measures that were maintained for up to 4 years. Long term follow-up is important and further supports the use of velmanase alfa as an effective and well-tolerated treatment for AM. Based on the currently available data set, no baseline characteristic can be predictive of treatment outcome. Early treatment during paediatric age showed better outcome in functional endpoints.

OriginalsprogEngelsk
TidsskriftJournal of Inherited Metabolic Disease
Vol/bind41
Udgave nummer6
Sider (fra-til)1225-1233
Antal sider9
ISSN0141-8955
DOI
StatusUdgivet - nov. 2018

ID: 56311059